🇺🇸 FDA

Intelligence · Clinical Pipeline

AstraZeneca Pipeline

All ClinicalTrials.gov programs at AstraZeneca — phase, modality, and trial IDs.

Programs
20

Quick answer

AstraZeneca has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. AZD0292

    AstraZeneca

    Bronchiectasis With Pseudomonas Aeruginosa Colonization

    phase 2 mab active

    1 trial

  2. AZD2265 (FPI-2265)

    AstraZeneca

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  3. AZD2281

    AstraZeneca

    Ovarian Neoplasms

    phase 2 small molecule completed

    1 trial

  4. AZD5363 when combined with weekly paclitaxel.

    AstraZeneca

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  5. AZD6793

    AstraZeneca

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  6. AZD8931

    AstraZeneca

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  7. AZD9668

    AstraZeneca

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  8. Atuliflapon

    AstraZeneca

    Asthma

    phase 2 small molecule completed

    1 trial

  9. Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

    AstraZeneca

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  10. Calquence 100 mg film-coated tablets

    AstraZeneca

    mantle cell lymphoma (MCL)

    phase 2 small molecule active

    1 trial

  11. Fostamatinib

    AstraZeneca

    Rheumatoid Arthritis

    phase 2 small molecule terminated

    1 trial

  12. Gefitinib

    AstraZeneca

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  13. MEDI4736

    AstraZeneca

    Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule completed

    1 trial

  14. Olaparib Continuous (28-Day cycle) 300 mg BD.

    AstraZeneca

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Osimertinib + Savolitinib

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Osimertinib 80 mg/40 mg

    AstraZeneca

    Stage II-IIIB Non-small Cell Lung Carcinoma

    phase 2 small molecule active

    1 trial

  17. Tozorakimab

    AstraZeneca

    Asthma

    phase 2 small molecule active

    1 trial

  18. Trastuzumab deruxtecan

    AstraZeneca

    Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

    phase 2 small molecule active

    1 trial

  19. Volrustomig

    AstraZeneca

    Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

    phase 2 mab active

    1 trial

  20. osimertinib

    AstraZeneca

    Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does AstraZeneca have?

20 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.